Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells.

Broad pipeline of clinical and next generation programs

Autolus pipeline diagram

NG = Next generation
SCLC = Small Cell Lung Cancer
* Subject to confirmation by regulatory authorities

Lead Clinical Programs

AUTO1 is a novel investigational CD19-targeting CAR T cell therapy designed to overcome the limitations in safety - while maintaining similar levels of efficacy - compared to current CD19 CAR T cell therapies.  AUTO1 has a fast target binding off-rate designed to minimize excessive activation and associated cytokine release, which may reduce toxicity. In addition, the fast off-rate may reduce T cell exhaustion, enhance persistence, and improve the programmed T cells' ability to engage in serial killing of target cancer cells. AUTO1 is Autolus’ most advanced program and recently entered a pivotal study in adult ALL and is also being evaluated in a Phase I study in pediatric ALL.

AUTO3 is a programmed T cell therapy containing two independent chimeric antigen receptors targeting CD19 and CD22 that have each been independently optimized for single target activity. By simultaneously targeting two B cell antigens, AUTO3 is designed to minimize relapse due to single antigen loss in patients with B cell malignancies. It has also been designed with a safety profile suitable for all settings of care, including outpatient therapy. AUTO3 is currently being tested in a Phase I study in diffuse large B cell lymphoma.

A programmed T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1, employing a novel and differentiated treatment approach. AUTO4 is designed to selectively kill cancerous T cells in a manner that we believe will preserve a portion of the patient’s normal, healthy T cells to maintain immunity. Since the AUTO4 approach is a novel mechanism to target T cells, Autolus has also programmed the product candidate with a “safety switch” in order to allow physicians to manage toxicity by eliminating the programmed T cells if a patient experiences severe adverse side effects from the treatment. AUTO4 is currently being tested in a Phase I study in TRBC1-positive peripheral T cell lymphoma.

A programmed T cell therapy targeting GD2 in development for the treatment of neuroblastoma. A Phase 1 clinical trial with AUTO6 is being sponsored and conducted by Cancer Research UK, or CRUK, and preliminary data has shown initial anti-tumor activity in this solid tumor indication. Autolus is developing a next-generation product candidate, AUTO6NG, incorporating additional programming modules designed to improve the efficacy, safety and persistence of AUTO6 which is currently in preclinical development.

This site uses cookies to improve user experience by collecting data. Please click 'Accept all and continue' to consent to our use of cookies or go to Privacy Settings to view the types of information collected and set your browsing preferences.